Suchergebnisse

Abstract
Over the past few decades, phthalate esters (PAEs) used as additives to improve the persistence and flexibility of polymeric materials. They are also used in cosmetics, insect repellents, and propellants, and their continuous input into drinking waters has constituted a serious risk to human health and the environment. DBPs are compounds classified as hazardous substances and have teratogenic properties. Due to the high bioaccumulation of DBP, they have toxic properties in different organisms, making it very important to remove PAEs before discharging them into environments. In this study a systematic review was designed to evaluate Advanced oxidation processes (AOPs) studies which have successfully treated contaminated water with PAEs. Among AOPs, particularly photocatalytic, UV/H2O2 photolysis, sonolysis, and ozone-based processes were more tried to degrade PAEs in aqueous solutions. Additionally, a more detail of each AOPs was explained. Findings showed that all advanced oxidation processes, especially combined AOPs have good results in the degradation of PAEs in water.

Abstract
Today microplastics (MPs) have received worldwide attention as an emerging environmental pollution which is one of the four major global environmental threat and health hazard to human as well. Unfortunately, MPs have been founded in the all environments and media include air, water resources, sediments, and soil. It should not be forgotten MPs have also been detected in food and processing products like tuna. MPs can be ingested by marine organisms such as zooplankton, fish and birds. Accumulation and distribution of MPs by commercially important aquatic organisms is expected to lead to greater exposure risk for human populations with possible adverse effects over time. The aim of this work was to review the published literature regarding the contamination of commercial fish muscle for human consumption. Furthermore, a short revision of the environmental contamination and human health effects by MPs are included. We also estimated human daily intake considering the worldwide contamination of commercial fish muscle ranged from 0.016 items/g muscle of fish to 6.06 items/g muscle of fish. MPs have been found in 56.5% of the commercial fish samples analysed here. As fish is used in human food table across the word, they constitute a long-term exposure route for all humans and raise the concern about the potential public health risk.

Abstract
Treatment with non-thermal plasma is a reliable technology to oxidize chemical impurities that exist in polluted water, wastewater, and leachate, those degradation-resistant and cannot be removed by conventional treatment methods. In this study, the effective factors affecting in the formation ofreactive oxygen species in non-thermal plasma treatment process, as a new advanced oxidation process method explianed. In this manner, all associated manuscripts existed in the main databases including Google Scholar, Science Direct, PubMed, and Open Access Journal Directory from 1990 until 2022 were explored. The utilized keywords were involved non-thermal plasma, Cold plasma, Measurement, •OH, O3 and UV. Overall, 8,813 articles were gathered and based on the relevance titles and abstracts, 18 paper were selected for further reviewing. In several studies, plasma techniques have been used to treat water, wastewater and leachate, but few studies have evaluated the factors influencing the production of ROS species by non-thermal plasma. The non-thermal plasma destroys pollutants by reactive free radicals spices (hydroxyl, hydrogen atoms, etc.) a combination effect of strong electric fields, energetically charged particles, and ultrasound. Some factors such as water vapor, hydraulic retention time, inter-electrode spacing, discharge power density, and aeration of the effluent as well as use of catalyst have direct effect on the reactive oxygen species formation. If these factors controlled within the best ranges, it will promote the oxidizing radical production and system performance. Also, high-energy electrons and oxidizing species produced in the cold plasma system can well degrade most of pollution in water and wastewater.

Abstract
Amoxicillin (AMX) is one of the antibiotics in the penicillin category that is used in various fields. Considering the harmful effects of its remains, it is necessary to survey the ways to remove this compound. Advanced oxidation process (AOPs), specially photo-Fenton has been used for the removal of AMX. This study has been conducted based on PubMed, Google Scholar, DOAJ, Web of Science, and Scopus databases during the years 2008–2019. Some factors such as the aquatic solution, light source characteristics, iron, and H2O2 concentration, AMX degradation percentage, removal of total organic carbon percentage, and AMX concentration have been surveyed to optimize the process. Studies showed that the photo-Fenton process is highly dependent on pH, and in most studies, the highest efficiency has been observed in acidic pH values. Using a more energy light source can be effective in reducing the use of catalysts and oxidizers. The combined methods of AOPs such as photo-Fenton, electro-Fenton, and photo-electro-Fenton have higher efficiency in increasing mineralization than the photon process. The use of synthetic wastewater has a higher efficiency in the degradation of AMX than in real wastewater in the photo-Fenton process, which can be due to the absence of the interfering agents in synthetic environments.

BACKGROUND:Achieving universal health coverage (UHC) involves all people receiving the health services they need, of high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and WHO's Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is important for understanding whether health services are aligned with countries' health profiles and are of sufficient quality to produce health gains for populations of all ages. METHODS:Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework developed through WHO's GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from reproductive and newborn to older adults (≥65 years). Effective coverage indicators were based on intervention coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; outcome-based measures were transformed to values on a scale of 0-100 based on the 2·5th and 97·5th percentile of location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of UHC effective coverage performance on the basis of pooled health spending per capita, representing UHC effective coverage index levels achieved in 2019 relative to country-level government health spending, prepaid private expenditures, and development assistance for health. To assess current trajectories towards the GPW13 UHC billion target-1 billion more people benefiting from UHC by 2023-we estimated additional population equivalents with UHC effective coverage from 2018 to 2023. FINDINGS:Globally, performance on the UHC effective coverage index improved from 45·8 (95% uncertainty interval 44·2-47·5) in 1990 to 60·3 (58·7-61·9) in 2019, yet country-level UHC effective coverage in 2019 still spanned from 95 or higher in Japan and Iceland to lower than 25 in Somalia and the Central African Republic. Since 2010, sub-Saharan Africa showed accelerated gains on the UHC effective coverage index (at an average increase of 2·6% [1·9-3·3] per year up to 2019); by contrast, most other GBD super-regions had slowed rates of progress in 2010-2019 relative to 1990-2010. Many countries showed lagging performance on effective coverage indicators for non-communicable diseases relative to those for communicable diseases and maternal and child health, despite non-communicable diseases accounting for a greater proportion of potential health gains in 2019, suggesting that many health systems are not keeping pace with the rising non-communicable disease burden and associated population health needs. In 2019, the UHC effective coverage index was associated with pooled health spending per capita (r=0·79), although countries across the development spectrum had much lower UHC effective coverage than is potentially achievable relative to their health spending. Under maximum efficiency of translating health spending into UHC effective coverage performance, countries would need to reach $1398 pooled health spending per capita (US$ adjusted for purchasing power parity) in order to achieve 80 on the UHC effective coverage index. From 2018 to 2023, an estimated 388·9 million (358·6-421·3) more population equivalents would have UHC effective coverage, falling well short of the GPW13 target of 1 billion more people benefiting from UHC during this time. Current projections point to an estimated 3·1 billion (3·0-3·2) population equivalents still lacking UHC effective coverage in 2023, with nearly a third (968·1 million [903·5-1040·3]) residing in south Asia. INTERPRETATION:The present study demonstrates the utility of measuring effective coverage and its role in supporting improved health outcomes for all people-the ultimate goal of UHC and its achievement. Global ambitions to accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable diseases occurs and countries can better translate health spending into improved performance. Focusing on effective coverage and accounting for the world's evolving health needs lays the groundwork for better understanding how close-or how far-all populations are in benefiting from UHC. FUNDING:Bill & Melinda Gates Foundation.